Advertisement

Topics

Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTA

03:30 EDT 14 Mar 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Press Release Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTATM Increase in Royalties by 1% on Annual VYZULTATM Global Sales Revenue Over $300 Million...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...